ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will ...
Pharmabiz2h
Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer
Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...
Business Insider10d
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
"We believe MRG007 is a potential best-in-class ADC for the treatment of GI malignancies based on preclinical and IND enabling studies,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent ...